MEDICAL DEVICE GUIDANCE JANUARY 2019
HEALTH SCIENCES AUTHORITY – HEALTH PRODUCTS REGULATION GROUP Page 11 of 29
*NOTE: For the purposes of this guidance, marketing authorisation would
refer to either (i) registration on the Singapore Medical Device Register (SMDR), (ii)
placement on the Transition-List or (iii) Special Authorisation Routes for local supply (GN-26,
GN-27, GN-29 or GN-30(CR).
NOTE: In cases where the medical devices affected by the FSCA have been
imported but not supplied in Singapore or have obtained marketing authorisation from the
Authority but have not been manufactured, imported or supplied in Singapore, a MDRR3
report form shall be submitted.
R3.5 ► NOTE: Under circumstances where there is a subsequent clinical need for
the devices affected by the FSCA reported under MDRR3, a review would be required prior to
any supply. Hence, a subsequent MDRR1 report should be submitted to the Authority. ◄
NOTE: In cases where the medical devices affected by the FSCA have been
manufactured in Singapore, a MDRR1 report form shall be submitted, regardless of whether
the affected medical devices have been supplied in Singapore.
4. WHO NEEDS TO NOTIFY FSCA TO THE AUTHORITY?
The party that performs the reporting obligations to the Authority is also
referred to as the reporting person. The dealer that manufactured, imported or
supplied or obtained marketing authorisation for the affected devices in
Singapore shall be the reporting person. In cases, where more than one
dealer has manufactured, imported or supplied the affected devices in
Singapore, each dealer that manufactured, imported or supplied the affected
devices may be required to report individually.
NOTE: However, in certain cases, if complete distribution and stock inventory details
on affected devices can be obtained from one or more of the reporting persons, report
submission from each of the dealers may not be requested by the Authority.